Loading
A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, now recruiting.
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer is a phase 2, interventional study registered as NCT05555888 by Fudan University, with a registry enrolment figure of 34 participants, started 2022-12-12 and due to reach its primary completion in 2024-03-12. Interventions recorded: PD-1 antibody; Capecitabine; Oxaliplatin; Short-course radiotherapy. Conditions listed: Early Low Rectal Cancer. Primary outcome: complete response (CR) rate. Sites: China. No results are recorded here; the registry entry is the source.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.